Hansoh Pharmaceutical Group Company Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hansoh Pharmaceutical Group Company Limited
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
- Contract Research, Toxicology Testing-CRO
- Contract Manufacturing Organization
- Generic Drugs
- Other Names / Subsidiaries
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.